Col14A1-derived tumor antigen polypeptide and use thereof

US11612643B2 · kind B2 · utility

Assignee

• GENOIMMUNE THERAPEUTICS CO., LTD. · CN

Inventors

• Bo Li · San Jose, US
• Geng Liu · Longbeilingcun, CN
• Si QIU · Longbeilingcun, CN
• Dongli Li · Longbeilingcun, CN
• Chongming Jiang · Longbeilingcun, CN
• Shuntao Luo · Tangxia, CN
• Xiumei Lin · Lo Wu, CN
• Ting An · Longbeilingcun, CN
• Yong Hou · Tangxia, CN
• Chengchi Chao · Longbeilingcun, CN
• Zhen Cheng · 红钢城街道, CN
• Handong Li · San Jose, US
• Naibo Yang · San Jose, US

Key dates

• Filing date: Sep 30, 2016
• Grant date: Mar 28, 2023
• Expiry date: Aug 6, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/15041
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are a tumour antigen polypeptide having the amino acid sequence as shown in SEQ ID NO: 2 or a variant thereof; a nucleic acid encoding same; a nucleic acid construct, an expression vector, and a host cell comprising the encoding nucleic acid; and an antigen presenting cell presenting the tumour antigen polypeptide on the cell surface and an immune effector cell thereof. Also provided is the use of the polypeptide, nucleic acid, antigen presenting cell or immune effector cell in the diagnosis, prevention and treatment of cancers.